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In Low and Middle-Income Countries (LMIC) almost all cancer
patients and their close relatives face some form of ﬁnancial
deprivation during the phases of diagnostic workup and treatment of cancer. The term ﬁnancial toxicity (FT) refers to the
detrimental eﬀects of the excess ﬁnancial burden caused by
the diagnosis of cancer on the well-being of patients, their families, and society.1 In cancer management this phenomenon of
ﬁnancial constraint becomes extremely important for both
patient and the healthcare provider. In LMIC, like in Pakistan,
the aﬀordability of patients plays a pivotal role in access to
healthcare. Financial toxicity leads to multifaceted challenges
for the patients. At each step, the patient and his or her family
members face various forms of psychological distress.
Patients undergoing cancer treatment are likely to experience
ﬁnancial toxicity due to the longer timeframe between diagnosis and treatment. Multiple modalities are available for treatment, e.g. surgery, radiation therapy, chemotherapy,
hormones, etc. Overall costs also include out-of-pocket costs
like transportation, residence, childcare, loss of income etc. To
address these issues eﬀective patient screening, transparent
pricing, and commitment to providing evidence-based high-quality care are important.2 Multidisciplinary approaches
provided by a team of experts will be required to provide solutions to this perpetual problem which demands expert mature
input from disciplines involved in the overall comprehensive
care of the cancer patients. As the problem is multifaceted,
therefore its solution will also require multipronged coping
strategies. All the stakeholders have to play their roles in their
domains. The list of stakeholders of the Financial Toxicity
Tumor Board is healthcare providers, patients, policymakers,
fund providers, and ﬁnancial councillors.3
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Exact measurement of ﬁnancial toxicities for families seeking
ﬁnancial assistance in cancer care is performed via meticulous documentation of appropriate socioeconomic details of
the household throughout treatment. It is imperative to identify strata of cancer patients who are relatively at the greatest
risk of experiencing ﬁnancial constraints. Financial councillors
can assist in this. An open deliberation between multi-disciplinary clinical and ﬁnance team members to ensure costing as
part of treatment plans is the desired process and objective of
1
FTTB to practically reduce the burden of ﬁnancial toxicity.
In a study published in June 2021 in the Journal of Clinical
Oncology, conducted at Levine Cancer Institute, North
Carolina, it was reported that the establishment of the ﬁnancial toxicity tumor board (FTTB) resulted in a net saving of
more than 60 million dollars of 1819 cancer patients’
4
expenses. Like any other multidisciplinary tumor board, this
tumor board also requires the maintenance of high-quality
parameters. Clinical quality indicators can be introduced in
the process to make sure that all board recommendations are
being made in full compliance with evidence-based
5
medicine. An online survey conducted in 2017 reported that
out of all cancer patients included in the survey, three-quarters experience some degree of ﬁnancial toxicity after the
diagnosis of cancer. The most common barrier was found to be
lack of resources which represented ﬁfty percent of all cases.
Other factors were complex documentary work requirements
for getting ﬁnancial assistance and partial or total unawareness of available ﬁnancial support and resources.6
In LMIC, this FT tumor board can prove itself as a useful entity
and breaking point where ﬁnancial status, disease status, and
cost of treatment are discussed in one room leading to open
debate and argument. In this tumor board, each stakeholder
will represent his or her domain while addressing each
patient’s case on clinical merit. The diﬀerence between strategies adopted in the scenarios of radical and palliative intents
of treatment would be clariﬁed to the non-medical team
members of the board. A regular sitting of multidisciplinary
stakeholders representing both clinical and ﬁnancial experts
will lead to a better cost-eﬀective and realistic tumor board
recommendation. Under no circumstances, clinicians would
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give any opinion in FTTB which does not lie inside the boundaries of evidence-based medicine. Multidisciplinary Tumor
Boards do play an important role in the overall care and
7
management of cancer patients treated in LMIC. We came
across some examples of FTTB in contemporary published
literature. Abbott et al. in their study published in the journal of
surgical oncology highlighted the importance of ﬁnancial
toxicity concerning other signiﬁcant factors originating from
inherent disparities between various strata of socio-economic
groups. The authors concluded that relevant utilization of telehealth can lead to lesser expenditure and it can potentially
minimise the overall cost of cancer treatment. It would result
8
in better patient compliance and a better clinical outcome.
Financial toxicity is a signiﬁcant issue that is quite relevant to
Pakistani patients. The healthcare system has many areas
which need improvement.9 We strongly recommend the establishment of multi-disciplinary tumor boards as a measure of
the quality and safety of patients. In our opinion, for devel10
oping countries, this is a lifeline for our patients. An example
of an independent non-institutional Tumor Board is the
Karachi City Tumor Board.11 Financial Toxicity Tumor Board
would be an innovative patient-centred initiative.
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